



DOCKET NO: B00801.70238.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ridker et al.
Serial No: 10/017,905
Confirmation No: 7653
Filed: December 14, 2001
For: INFLAMMATORY MARKERS AS TOOLS IN THE
DETECTION AND PREVENTION OF DIABETES
MELLITUS AND AS TOOLS TO AID IN THE
SELECTION OF AGENTS TO BE USED FOR THE
PREVENTION AND TREATMENT OF DIABETES
Examiner: unknown
Art Unit: 1646


RECEIVED

MAR 12 2003

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 3 day of March, 2003.


Edward R. Gates, Reg. No. 31,616

Commissioner for Patents
Washington, D.C. 20231

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case. No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

PART III: Compliance with 37 CFR §1.704(d)

Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart application and this communication was not received by the office of the undersigned more than 30 days prior to filing of this Information Disclosure Statement.

PART IV: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Serial No.: 10/017,905

- 3 -

Art Unit: 1646

Respectfully submitted,
Ridker et al., *Applicants*

By: Edward R. Gates


Edward R. Gates, Reg. No. 31,616
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 720-3500

Docket No. B00801.70238.US

Date: March 3, 2003

XNDDX

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/017,905	ATTY. DOCKET NO.: B00801.70238.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: December 14, 2001	CONFIRMATION NO.: 7653
		APPLICANT: Ridker et al.	
Sheet 1 of 1		GROUP ART UNIT: 1646	EXAMINER: unknown



U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C1	El-Nawawy, A. et al., "Interleukin-1-β, Tumor Necrosis Factor-α, Insulin Secretion and Oral Glucose Tolerance in Non-Diabetic Siblings of Children with IDDM," <i>Indian J. Pediatr.</i> 1998; 65: 455-460.	
	C2	Kallmann, B.A., et al. "Cytokine secretion patterns in twins discordant for Type I diabetes," <i>Diabetologia</i> 1999; 42: 1080-1085.	
	C3	Kretowski, A. et al., "The immune markers of preclinical phase of type 1 diabetes mellitus. The role of cytokines, adhesion molecules and peripheral blood lymphocyte subpopulations in the pathogenesis and prediction of insulin-dependent diabetes," <i>Przegląd Lekarski</i> 2000; 57: (12) 736-742.	
	C4	Kretowski, A. et al., "In Vitro Secretion of Interleukin 2 and Expression of IL-2 Receptor in Peripheral Blood Lymphocytes in High Risk of Insulin-Dependent Diabetes Mellitus Subjects," <i>Archivum Immunologiae et Therapiae Experimentalis</i> 1999; 47: 45-49.	
	C5	Kretowski, A. et al., "Nicotinamide inhibits enhanced in vitro production of interleukin-12 and tumour necrosis factor-α in peripheral whole blood of people at high risk of developing Type 1 diabetes and people with newly diagnosed Type 1 diabetes," <i>Diabetes Research and Clinical Practice</i> 2000; 47: 81-86.	
	C6	Szelachowska, M. et al., "Increased In Vitro Interleukin-12 Production by Peripheral Blood in High-Risk IDDM First Degree Relatives," <i>Horm Metab. Res.</i> 1997; 29: 168-171.	
	C7	PCT International Search Report for PCT/US01/48349, Date Search Completed: January 8, 2003.	

EXAMINER	DATE CONSIDERED
----------	-----------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

RECEIVED

MAR 12 2003